Practical experiences with eribulin in patients with metastatic breast cancer
There is currently no standard therapy for women with metastatic or locally recurrent breast cancer. The microtubule polymerization inhibitor eribulin, approved in March 2011, is the first monochemotherapy with a proven survival benefit and tolerable toxicity in this patient group. Using a retrospec
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
[2016]
|
| In: |
Anti-cancer drugs
Year: 2016, Volume: 27, Issue: 2, Pages: 112-117 |
| ISSN: | 1473-5741 |
| DOI: | 10.1097/CAD.0000000000000288 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1097/CAD.0000000000000288
|
| Author Notes: | Hans Tesch and Andreas Schneeweiss |
| Summary: | There is currently no standard therapy for women with metastatic or locally recurrent breast cancer. The microtubule polymerization inhibitor eribulin, approved in March 2011, is the first monochemotherapy with a proven survival benefit and tolerable toxicity in this patient group. Using a retrospec |
|---|---|
| Item Description: | Gesehen am 20.05.2020 |
| Physical Description: | Online Resource |
| ISSN: | 1473-5741 |
| DOI: | 10.1097/CAD.0000000000000288 |